Data reporting in ophthalmology during COVID-19 pandemic: need for a Canadian registryRegistries assist public health in documenting the incidence of new infections and gathering clinical data about patients to inform clinicians on presentation and evolution of emerging diseases. This becomes even more important during the coronavirus disease 2019 (COVID-19) pandemic.
Keratoconjunctivitis as the initial medical presentation of the novel coronavirus disease 2019 (COVID-19)A 29-year-old, otherwise healthy woman presented to the emergency eye clinic with a 1-day history of right eye conjunctivitis, photophobia, and clear watery discharge from the right eye. She returned from a 1-month vacation in the Philippines 3 days before presentation; she spent 1 day in San Francisco en route to her return to Canada. During her time in the Philippines, she swam in the ocean and hotel swimming pools. She was feeling well on her date of return on February 29 (Fig. 1). In Canada, she visited a public swimming pool the day after return.
Case of Ab Interno Trabeculectomy in Juvenile Open-angle Glaucoma with 5-year Follow-upJuvenile open-angle glaucoma (JOAG) is a subset of primary open-angle glaucoma (POAG) affecting those between 3 and 40 years of age and often with a more progressive course compared to POAG.1,2 Transmission is typically autosomal dominant with mutations identified in the myocilin (MYOC) and CYP1B1 genes.2
Childhood glaucoma in neonatal Marfan syndrome resulting from a novel FBN1 deletionMarfan syndrome (MFS) is an autosomal dominant genetic disorder of the connective tissue. The majority of MFS cases involve mutations in the FBN1 gene encoding the protein fibrillin-1. Fibrillin-1 is a protein found in the extracellular matrix that is incorporated into the final structure of microfibrils.1 In 25% of cases, the disorder occurs sporadically.2 The most common clinical manifestations resulting from MFS are musculoskeletal, cardiovascular, and ophthalmic. Patients with MFS often present with tall stature, arachnodactyly, and scoliosis, but the severity of the disease varies.
Serial intracameral bevacizumab for uveitis-glaucoma-hyphema syndrome: a case reportUveitis-glaucoma-hyphema (UGH) syndrome is characterized by chronic pseudophakic inflammation and recurrent hyphema typically associated with poorly manufactured or malpositioned intraocular lenses (IOLs) chafing against uveal tissue. Although the definitive treatment for UGH is IOL explantation, conservative treatments including topical steroid and nonsteroid agents and cyclophotocoagulation1 may be used. We report a case of UGH syndrome in a patient who did not respond well to conservative measures but has been relatively stable with serial bevacizumab injections.